<![CDATA[Ateganosine Combo Demonstrates Disease Control in Third-Line NSCLC]]>
Read the full articleYou might also wanna read
A Non-interventional, Real-world Study on the Adjuvant Treatment of Chinese EGFR-positive Stage IA NSCLC Patients With High-risk Factors Using Third-generation EGFR-TKIs.
Conditions : Non-Small Cell Lung Cancer; Adjuvant Therapy Interventions : Drug: Third-generation EGFR-TKI Sponsors : First Affiliated Hospit
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
Conditions : NSCLC; EGFR Activating Mutation; EGFR-TKI-resistant Non-Small Cell Lung Cancer; Trop2; PET/CT Imaging Interventions : Diagnosti
MRG003 With Gemcitabine for Second-line Advanced PDAC
Conditions : Pancreatic Ductal Adenocarcinoma (PDAC); Second Line Treatment Interventions : Drug: becotatugvedotin plus gemcitabine Sponsors
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small C
Conditions : Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC) Interventions : Drug: Pumita
Comments
Sign in to join the conversation.
No comments yet. Be the first.